Evropská unie - němčina - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - schweine - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Evropská unie - němčina - EMA (European Medicines Agency)

intervacc ab - recombinant streptococcus equi protein cce, recombinant streptococcus equi protein eq85, recombinant streptococcus equi protein idee - immunologische tests für equiden - pferde - for the active immunisation to reduce clinical signs and the number of abscesses in acute stage of infection with s. equi.

Evropská unie - němčina - EMA (European Medicines Agency)

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - schweine - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

Německo - němčina - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

vifor france (8013858) - lithiumsulfat - retardtablette - teil 1 - retardtablette; lithiumsulfat (03789) 660 milligramm

Německo - němčina - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

vifor fresenius medical care renal pharma france (8159237) - calcifediol-monohydrat - weichkapsel, retardiert - 30 mikrogramm - calcifediol-monohydrat (28550) 0,03 milligramm

Německo - němčina - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

vifor france (8013858) - eisen(iii)-carboxymaltose x-y kda ((mit angabe des bereichs x-y der massen-gemittelten partikelmasse in kda (kilodalton, kg/mol))) - sirup - teil 1 - sirup; eisen(iii)-carboxymaltose x-y kda ((mit angabe des bereichs x-y der massen-gemittelten partikelmasse in kda (kilodalton, kg/mol))) (13974) 37 milligramm

Německo - němčina - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

vifor france (8013858) - eisen(ii)-fumarat - retardkapsel - teil 1 - retardkapsel; eisen(ii)-fumarat (02781) 304,2 milligramm

Německo - němčina - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

vifor france - eisen(iii)-hydroxid-sucrose-wasser-komplex - konzentrat zur herstellung einer injektionslösung oder infusionslösung - eisen(iii)-hydroxid-sucrose-wasser-komplex 2700.mg

Německo - němčina - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

vifor france (8013858) - eisen(iii)-carboxymaltose x-y kda ((mit angabe des bereichs x-y der massen-gemittelten partikelmasse in kda (kilodalton, kg/mol))) - tropfen zum einnehmen, lösung - teil 1 - tropfen zum einnehmen, lösung; eisen(iii)-carboxymaltose x-y kda ((mit angabe des bereichs x-y der massen-gemittelten partikelmasse in kda (kilodalton, kg/mol))) (13974) 178,6 milligramm

Německo - němčina - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

vifor france (8013858) - eisen(iii)-carboxymaltose x-y kda ((mit angabe des bereichs x-y der massen-gemittelten partikelmasse in kda (kilodalton, kg/mol))) - injektions-/infusionslösung - teil 1 - injektions-/infusionslösung; eisen(iii)-carboxymaltose x-y kda ((mit angabe des bereichs x-y der massen-gemittelten partikelmasse in kda (kilodalton, kg/mol))) (13974) 180 milligramm